CEM/C1(ICGE-CEM/C1,IC-39671)
| Organism | Homo sapiens, human |
|---|---|
| Tissue | peripheral blood |
| Cell Type | T lymphoblast |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | acute lymphoblastic leukemia |
| Age | 4 years |
| Gender | Female |
| Ethnicity | Caucasian |
| Storage Conditions | liquid nitrogen vapor phase |
|
|
|
|---|---|
| Derivation |
CEM/C1 is a camptothecin (CPT) resistant derivative of the human T cell leukemia cell line CCRF-CEM (see ATCC CCL-119). The cell line was selected and subcloned in 1991 for resistance to CPT.
|
| Clinical Data |
4 years
Caucasian
female
|
| Comments |
This cell line exhibits cross resistance to both the water soluble (topotecan) and water insoluble (9-amino-CPT and 10,11-methylenedioxy-CPT) analogs of CPT. CEM/C1 cells are approximately 31 fold less sensitive to CPT than the parental CEM cells.
CEM/C1 cells display atypical multidrug resistance (MDR) and altered topoisomerase I catalytic activity.
Resistance to CPT is stable for up to six months.
|
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%. |
|---|---|
| Subculturing |
Cultures can be maintained by addition or replacement of medium. When replacing media, centrifuge cells and resuspend cell pellet in fresh medium at 1- 2 x 105 viable cells/mL. Maintain cultures at cell concentrations between 1 x 105 and 2 x 106 viable cells/mL. Medium Renewal: 2 to 3 times a week. |
| Cryopreservation |
culture medium 95%; DMSO, 5%
|
| Culture Conditions |
Temperature: 37°C
|
